SCHEMBL2927964

SCHEMBL2927964

COc1cc(C(CC(=O)Nc2ccc(Br)cn2)N2Cc3ccccc3C2=O)cc(OC)c1OC

nearest known ligand 0.83

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.83
MEN1 O00255 2/20 0.79
MAPT P10636 2/20 0.78
TP53 P04637 5/20 0.73
RAB9A P51151 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925370 0.92 MAPT (0.80) KMT2AMEN1MAPTTP53RAB9A
SCHEMBL2926423 0.91 KMT2A (1.00) KMT2AMEN1MAPTTP53RAB9A
SCHEMBL2924479 0.90 KMT2A (0.83) KMT2AMEN1MAPTTP53RAB9A
SCHEMBL2928990 0.88 KMT2A (1.00) KMT2AMEN1MAPTTP53RAB9A
SCHEMBL2923701 0.85 MAPT (0.82) KMT2AMEN1MAPTTP53RAB9A
SCHEMBL2929724 0.83 KMT2A (0.79) KMT2AMEN1MAPTTP53RAB9A
SCHEMBL2922120 0.83 KMT2A (0.85) KMT2AMEN1MAPTTP53RAB9A
SCHEMBL2930706 0.82 KMT2A (0.70) KMT2AMEN1MAPTTP53RAB9A
SCHEMBL2927891 0.81 KMT2A (0.75) KMT2AMEN1MAPTTP53
SCHEMBL2923592 0.80 KMT2A (0.80) KMT2AMEN1MAPTTP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431602-B2 Beta-amino acid derivatives for treatment of diabetes MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-04-30 US claimed
EP-2231640-B1 BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2012-06-06 EP claimed
US-20100331346-A1 BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-12-30 US claimed
CN-101925596-A Beta-amino acid derivatives for treatment of diabetes MERCK PATENT GMBH 2010-12-22 CN claimed
EP-2231640-A1 BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES Merck Patent GmbH (DE) 2010-09-29 EP claimed
WO-2009092432-A1 BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-07-30 WO claimed
US-8431602-B2 Beta-amino acid derivatives for treatment of diabetes MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-04-30 US disclosed
EP-2231640-B1 BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2012-06-06 EP disclosed
US-20100331346-A1 BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-12-30 US disclosed
CN-101925596-A Beta-amino acid derivatives for treatment of diabetes MERCK PATENT GMBH 2010-12-22 CN disclosed
EP-2231640-A1 BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES Merck Patent GmbH (DE) 2010-09-29 EP disclosed
WO-2009092432-A1 BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331346-A1 BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES GPR119, GLS, GCKR KMT2A 3191/4885MEN1 3909/4885MAPT 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.